GHRS

GH Research PLC

Healthcare · Biotechnology

$152.61 sample

+1.67 (+1.11%) 1D

Market cap

$702.0B

Price as of

2026-10-04

Latest filing

8-K · 2026-09-17

Alerts

8

Price$152.61 +1.96% 3M daily closessample

160.18149.02

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 25INSInsider sell: Chief Executive Officer
Sep 17SECDEF 14A filed
Sep 08INSInsider sell: Director
Aug 28INSInsider buy: EVP, Operations
Aug 24SECForm 144 filed
Aug 18INSInsider buy: Director
Aug 13INSInsider sell: General Counsel
Aug 07INSInsider buy: Chief Financial Officer

Sign up to see the real GHRS record →

Company facts

SEC EDGAR registration

Name: GH Research PLC
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +53sample, -100 to +100
Reporting currency: USD

Who is positioning in GHRS

sample

Insiders: 9 insider transactions over 90 days, net selling, $20.9M
Congress: 2 members traded over 90 days
Institutions · 13F: 13 funds hold $3.6B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$21.0B +16.6% y/y

Q4 2024Q3 2026

Inventory$12.7B +16.5% y/y

Q4 2024Q3 2026

Accounts receivable$9.3B +9.0% y/y

Q4 2024Q3 2026

Total debt$24.8B +14.0% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $551.4B -7.8% 3M
Sample peer B: $608.8B +10.7% 3M
Sample peer C: $114.2B +14.2% 3M
Sample peer D: $496.9B +15.1% 3M
Sample peer E: $192.9B +11.8% 3M